Free Trial

Sutro Biopharma's (STRO) Neutral Rating Reiterated at HC Wainwright

Sutro Biopharma logo with Medical background

HC Wainwright reaffirmed their neutral rating on shares of Sutro Biopharma (NASDAQ:STRO - Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $2.00 price objective on the stock.

A number of other equities research analysts have also commented on the company. Wedbush lowered Sutro Biopharma from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $8.00 to $2.00 in a research report on Friday, March 14th. Bank of America cut Sutro Biopharma from a "buy" rating to an "underperform" rating and cut their price target for the company from $11.00 to $1.00 in a report on Friday, March 14th. Citizens Jmp lowered shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a report on Friday, March 14th. Finally, Piper Sandler set a $2.00 target price on shares of Sutro Biopharma in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $6.63.

Read Our Latest Report on Sutro Biopharma

Sutro Biopharma Stock Up 2.8 %

NASDAQ:STRO traded up $0.03 during trading hours on Tuesday, reaching $1.10. The company had a trading volume of 1,240,564 shares, compared to its average volume of 1,075,312. The firm has a market capitalization of $92.80 million, a PE ratio of -0.68 and a beta of 1.77. The stock has a 50-day moving average of $0.91 and a two-hundred day moving average of $1.93. Sutro Biopharma has a one year low of $0.52 and a one year high of $5.17.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The firm had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10.44 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same period in the prior year, the business earned ($1.78) earnings per share. As a group, sell-side analysts expect that Sutro Biopharma will post -2.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd acquired a new position in Sutro Biopharma in the fourth quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Sutro Biopharma in the 4th quarter valued at $32,000. Virtu Financial LLC acquired a new position in shares of Sutro Biopharma in the 3rd quarter valued at $77,000. Vontobel Holding Ltd. boosted its position in shares of Sutro Biopharma by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company's stock worth $46,000 after purchasing an additional 10,000 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Sutro Biopharma by 74.3% during the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock worth $50,000 after purchasing an additional 11,494 shares during the period. Institutional investors own 96.99% of the company's stock.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

Recommended Stories

Analyst Recommendations for Sutro Biopharma (NASDAQ:STRO)

Should You Invest $1,000 in Sutro Biopharma Right Now?

Before you consider Sutro Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.

While Sutro Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines